Montelukast Dura

Montelukast, the active ingredient in Montelukast Dura, is a leukotriene receptor antagonist presented as a tablet (strength not specified) for oral use. It is used to manage asthma and allergic rhinitis, helping to prevent bronchoconstriction and reduce inflammation in patients with these respiratory conditions.

GNH USA supplies Montelukast Dura as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, adhering to stringent quality standards and regulatory requirements across multiple markets, with reliable logistics and support for customers.

Montelukast acts on the leukotriene pathway to control respiratory disorders. - Asthma: improves long‑term control and reduces the frequency of asthma attacks. - Exercise‑induced bronchoconstriction: prevents narrowing of airways during physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate pain in the head. - Upper respiratory infection: symptoms such as sore throat or runny nose. - Abdominal pain: discomfort in the stomach area. - Cough: persistent dry cough. - Dyspepsia: indigestion or upset stomach. - Fever: mild temperature elevation.

Serious or Rare Side Effects: - Allergic reactions: rash, swelling, or anaphylaxis. - Mood changes: depression, suicidal thoughts, or agitation. - Hepatotoxicity: signs of liver injury such as jaundice or elevated enzymes.

Before prescribing Montelukast Dura, consider the following precautions to ensure safe use. - Assess medical history: confirm no prior hypersensitivity to montelukast or related compounds. - Monitor psychiatric status: watch for mood changes, depression or suicidal thoughts. - Evaluate liver function: consider baseline tests in patients with hepatic impairment. - Use in children: follow pediatric guidelines and age‑specific safety data. - Pregnancy and lactation: discuss potential risks with the prescriber; data are limited. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Montelukast can interact with other medicines; awareness of key interactions helps avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital: may decrease montelukast plasma concentrations. - Rifampin: induces metabolism, potentially lowering therapeutic effect.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase risk of neuropsychiatric events. - CYP3A4 inhibitors (ketoconazole, erythromycin): could raise montelukast levels. - Warfarin: monitor INR as montelukast may affect anticoagulation.